Markus Cornberg

Markus Cornberg's AcademicInfluence.com Rankings

Markus Cornberg

Computer Science

#6805

World Rank

#7170

Historical Rank

Machine Learning

#2326

World Rank

#2354

Historical Rank

Artificial Intelligence

#2602

World Rank

#2643

Historical Rank

Database

#3882

World Rank

#4038

Historical Rank

computer-science Degrees

Download Badge

Computer Science

Why Is Markus Cornberg Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Markus Cornberg's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study. (2018) (1034)
Treatment of acute hepatitis C with interferon alfa-2b. (2001) (823)
Treating viral hepatitis C: efficacy, side effects, and complications (2006) (697)
Natural killer cells act as rheostats modulating antiviral T cells (2011) (545)
The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm (2014) (477)
Mapping the human genetic architecture of COVID-19 (2021) (455)
A systematic review of hepatitis C virus epidemiology in Europe, Canada and Israel (2011) (428)
Hepatitis B surface antigen (HBsAg) levels in the natural history of hepatitis B virus (HBV)-infection: a European perspective. (2010) (399)
Care of patients with liver disease during the COVID-19 pandemic: EASL-ESCMID position paper (2020) (395)
Hepatitis B surface antigen quantification: why and how to use it in 2011 - a core group report. (2011) (309)
Historical epidemiology of hepatitis C virus (HCV) in selected countries (2014) (295)
Update of the statements on biology and clinical impact of occult hepatitis b virus infection. (2019) (285)
The role of quantitative hepatitis B surface antigen revisited. (2017) (254)
Early monotherapy with pegylated interferon alpha‐2b for acute hepatitis C infection: The HEP‐NET acute‐HCV‐II study (2006) (253)
Strategies to manage hepatitis C virus (HCV) disease burden (2014) (218)
Late HDV RNA relapse after peginterferon alpha‐based therapy of chronic hepatitis delta (2014) (217)
Long-term response after stopping tenofovir disoproxil fumarate in non-cirrhotic HBeAg-negative patients - FINITE study. (2017) (193)
Hepatitis E virus infection as a cause of graft hepatitis in liver transplant recipients (2010) (192)
Expression of leptin and leptin receptor isoforms in the human stomach (2000) (191)
Memory of mice and men: CD8+ T‐cell cross‐reactivity and heterologous immunity (2006) (187)
Interferon-alpha-induced TRAIL on natural killer cells is associated with control of hepatitis C virus infection. (2010) (186)
[Prophylaxis, diagnosis and therapy of hepatitis C virus (HCV) infection: the German guidelines on the management of HCV infection]. (2018) (185)
[Prophylaxis, diagnosis and therapy of hepatitis B virus infection - the German guideline]. (2011) (181)
Cross-reactive influenza virus-specific CD8+ T cells contribute to lymphoproliferation in Epstein-Barr virus-associated infectious mononucleosis. (2005) (173)
Private specificities of CD8 T cell responses control patterns of heterologous immunity (2005) (156)
Narrowed TCR repertoire and viral escape as a consequence of heterologous immunity. (2006) (153)
Hepatitis E virus (HEV)‐specific T‐cell responses are associated with control of HEV infection (2012) (146)
Proinflammatory cytokines trigger MUC gene expression and mucin release in the intestinal cancer cell line LS180 (2000) (145)
COVID-19 immune signatures reveal stable antiviral T cell function despite declining humoral responses (2020) (143)
EASL position paper on the use of COVID-19 vaccines in patients with chronic liver diseases, hepatobiliary cancer and liver transplant recipients (2021) (140)
Nonreversible MAIT cell‐dysfunction in chronic hepatitis C virus infection despite successful interferon‐free therapy (2016) (138)
In vivo evidence for ribavirin-induced mutagenesis of the hepatitis E virus genome (2016) (136)
CD8 memory T cells: cross-reactivity and heterologous immunity (2004) (126)
Guidance for Design and Endpoints of Clinical Trials in Chronic Hepatitis B—Report From the 2019 EASL‐AASLD HBV Treatment Endpoints Conference (2019) (122)
Guidance for Design and Endpoints of Clinical Trials in Chronic Hepatitis B—Report From the 2019 EASL‐AASLD HBV Treatment Endpoints Conference (2019) (122)
Treatment of chronic hepatitis B. (2010) (120)
Global timing of hepatitis C virus elimination in high‐income countries (2019) (118)
Impact of COVID-19 on the care of patients with liver disease: EASL-ESCMID position paper after 6 months of the pandemic (2020) (116)
Dual Function of the NK Cell Receptor 2B4 (CD244) in the Regulation of HCV-Specific CD8+ T Cells (2011) (113)
Hepatitis B core-related antigen (HBcrAg) levels in the natural history of hepatitis B virus infection in a large European cohort predominantly infected with genotypes A and D. (2015) (112)
Viral and Host Responses After Stopping Long-term Nucleos(t)ide Analogue Therapy in HBeAg-Negative Chronic Hepatitis B. (2016) (111)
Direct-Acting Antiviral-Induced Hepatitis C Virus Clearance Does Not Completely Restore the Altered Cytokine and Chemokine Milieu in Patients With Chronic Hepatitis C. (2016) (108)
Guidance for design and endpoints of clinical trials in chronic hepatitis B - Report from the 2019 EASL-AASLD HBV Treatment Endpoints Conference. (2019) (106)
Ledipasvir plus sofosbuvir fixed-dose combination for 6 weeks in patients with acute hepatitis C virus genotype 1 monoinfection (HepNet Acute HCV IV): an open-label, single-arm, phase 2 study. (2017) (106)
Compromised function of natural killer cells in acute and chronic viral hepatitis. (2014) (103)
Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study. (2022) (103)
Eligibility and Safety of Triple Therapy for Hepatitis C: Lessons Learned from the First Experience in a Real World Setting (2013) (103)
Improvement of liver function parameters in advanced HCV‐associated liver cirrhosis by IFN‐free antiviral therapies (2015) (100)
Prophylaxis, diagnosis and therapy of hepatitis B virus (HBV) infection: the German guidelines for the management of HBV infection. (2007) (99)
Long‐term follow‐up after successful interferon therapy of acute hepatitis C (2004) (97)
Delayed versus immediate treatment for patients with acute hepatitis C: a randomised controlled non-inferiority trial. (2013) (96)
Reappearance of effector T cells is associated with recovery from COVID-19 (2020) (93)
Drug-Drug Interactions With Novel All Oral Interferon-Free Antiviral Agents in a Large Real-World Cohort. (2016) (93)
Correlation between the Elecsys HBsAg II assay and the Architect assay for the quantification of hepatitis B surface antigen (HBsAg) in the serum. (2011) (88)
CD8 T Cell Cross-Reactivity Networks Mediate Heterologous Immunity in Human EBV and Murine Vaccinia Virus Infections (2010) (86)
Early IFN-α signatures and persistent dysfunction are distinguishing features of NK cells in severe COVID-19 (2021) (86)
Treatment of chronic hepatitis C with PEGylated interferon and ribavirin (2002) (83)
Clonal Exhaustion as a Mechanism to Protect Against Severe Immunopathology and Death from an Overwhelming CD8 T Cell Response (2013) (83)
Hepatitis B virus-specific T cell responses after stopping nucleos(t)ide analogue therapy in HBeAg-negative chronic hepatitis B. (2018) (81)
Treatment with daily consensus interferon (CIFN) plus ribavirin in non-responder patients with chronic hepatitis C: a randomized open-label pilot study. (2006) (81)
Hepatitis B Surface Antigen (Hbsag) Decrease and Serum Interferon-Inducible Protein-10 Levels as Predictive Markers for Hbsag Loss during Treatment with Nucleoside/Nucleotide Analogues (2011) (78)
Antiviral treatment and liver‐related complications in hepatitis delta (2017) (76)
Peginterferon alfa-2a plus tenofovir disoproxil fumarate for hepatitis D (HIDIT-II): a randomised, placebo controlled, phase 2 trial. (2019) (71)
[Prophylaxis, Diagnosis and Therapy of Hepatitis-B-Virus-(HBV-)Infection: upgrade of the guideline, AWMF-Register 021/011]. (2007) (68)
Treating chronic hepatitis delta: The need for surrogate markers of treatment efficacy. (2019) (67)
[Expert opinion on boceprevir- and telaprevir-based triple therapies of chronic hepatitis C]. (2012) (63)
Clinical value of on-treatment HCV RNA levels during different sofosbuvir-based antiviral regimens. (2016) (62)
Clinical and virological heterogeneity of hepatitis delta in different regions world‐wide: The Hepatitis Delta International Network (HDIN) (2018) (60)
Safety and Effectiveness of Direct-Acting Antiviral Agents for Treatment of Patients With Chronic Hepatitis C Virus Infection and Cirrhosis. (2016) (59)
Chronic hepatitis C virus infection irreversibly impacts human natural killer cell repertoire diversity (2018) (58)
Prevalence of HBV genotypes in Central and Eastern Europe (2008) (56)
Reduced dose and duration of peginterferon alfa-2b and weight-based ribavirin in patients with genotype 2 and 3 chronic hepatitis C. (2011) (55)
Interferon‐free therapy of chronic hepatitis C with direct‐acting antivirals does not change the short‐term risk for de novo hepatocellular carcinoma in patients with liver cirrhosis (2018) (53)
Exploring beyond clinical routine SARS-CoV-2 serology using MultiCoV-Ab to evaluate endemic coronavirus cross-reactivity (2021) (52)
Clinical outcomes following DAA therapy in patients with HCV-related cirrhosis depend on disease severity. (2020) (52)
Hepatitis A virus infection suppresses hepatitis C virus replication and may lead to clearance of HCV. (2006) (52)
Treatment of acute hepatitis C: the success of monotherapy with (pegylated) interferon alpha. (2008) (51)
Increased NK Cell Function After Cessation of Long-Term Nucleos(t)ide Analogue Treatment in Chronic Hepatitis B Is Associated With Liver Damage and HBsAg Loss (2018) (51)
Chronic hepatitis delta virus infection leads to functional impairment and severe loss of MAIT cells. (2019) (51)
Regulation of cytosolic free calcium concentration by extracellular nucleotides in human hepatocytes. (1999) (51)
A heterogeneous hierarchy of co-regulatory receptors regulates exhaustion of HCV-specific CD8 T cells in patients with chronic hepatitis C. (2015) (51)
Dominance of hepatitis C virus (HCV) is associated with lower quantitative hepatitis B surface antigen and higher serum interferon-γ-induced protein 10 levels in HBV/HCV-coinfected patients. (2015) (51)
Repeated Measurements of Hepatitis B Surface Antigen Identify Carriers of Inactive HBV During Long-term Follow-up. (2016) (49)
Loss of Anti-Viral Immunity by Infection with a Virus Encoding a Cross-Reactive Pathogenic Epitope (2012) (47)
Development and evaluation of a baseline-event-anticipation score for hepatitis delta (2014) (47)
Hepatitis B Surface Antigen Concentrations in Patients with HIV/HBV Co-Infection (2012) (46)
Protection against Vaccinia Virus Challenge by CD8 Memory T Cells Resolved by Molecular Mimicry (2006) (45)
The role of HBsAg levels in the current management of chronic HBV infection (2014) (45)
Clearance of low levels of HCV viremia in the absence of a strong adaptive immune response (2007) (45)
Elimination of Hepatitis C Virus has limited impact on the functional and mitochondrial impairment of HCV-specific CD8+ T cell responses. (2019) (45)
Functional and phenotypic characterization of peptide-vaccine-induced HCV-specific CD8+ T cells in healthy individuals and chronic hepatitis C patients. (2007) (44)
Whom? When? How? Another piece of evidence for early treatment of acute hepatitis C (2004) (44)
Caspase activation is required for antiviral treatment response in chronic hepatitis C virus infection (2006) (44)
The clinical significance of drug–drug interactions in the era of direct‐acting anti‐viral agents against chronic hepatitis C (2013) (44)
Cross-genotype-reactivity of the immunodominant HCV CD8 T-cell epitope NS3-1073. (2008) (43)
Effects of HDV infection and pegylated interferon α treatment on the natural killer cell compartment in chronically infected individuals (2014) (43)
Anti-HDV IgM as a Marker of Disease Activity in Hepatitis Delta (2014) (42)
P0772 : Daclatasvir plus sofosbuvir with or without ribavirin for the treatment of HCV in patients with severe liver disease: Interim results of a multicenter compassionate use program (2015) (42)
Aktualisierung der S3-Leitlinie zur Prophylaxe, Diagnostik und Therapie der Hepatitis-B-Virusinfektion AWMF-Register-Nr.: 021/011 Prophylaxis, Diagnosis and Therapy of Hepatitis B Virus Infection - (2011) (41)
Real-world effectiveness and safety of glecaprevir/pibrentasvir for the treatment of patients with chronic HCV infection: a meta-analysis. (2020) (41)
Treatment of HCV genotype 2 with sofosbuvir and ribavirin results in lower sustained virological response rates in real life than expected from clinical trials (2017) (41)
Interferon α-stimulated natural killer cells from patients with acute hepatitis C virus (HCV) infection recognize HCV-infected and uninfected hepatoma cells via DNAX accessory molecule-1. (2012) (41)
The Privacy of T Cell Memory to Viruses (2006) (40)
Real‐world use, effectiveness and safety of anti‐viral treatment in chronic hepatitis C genotype 3 infection (2017) (40)
Phase III results of Boceprevir in treatment naïve patients with chronic hepatitis C genotype 1 (2012) (40)
Interpreting T-Cell Cross-reactivity through Structure: Implications for TCR-Based Cancer Immunotherapy (2017) (40)
The German Hep-Net acute hepatitis C cohort: impact of viral and host factors on the initial presentation of acute hepatitis C virus infection. (2009) (39)
Mycophenolate mofetil in combination with recombinant interferon alfa-2a in interferon-nonresponder patients with chronic hepatitis C. (2002) (38)
Hepatitis D virus‐specific cytokine responses in patients with chronic hepatitis delta before and during interferon alfa‐treatment (2011) (38)
Clearance of Chronic HCV Infection During Acute Delta Hepatitis (2009) (38)
PREDICTION OF SUSTAINED RESPONSE AFTER NUCLEO(S)TIDE ANALOGUE CESSATION USING HBSAG AND HBCRAG LEVELS - A MULTICENTER STUDY (CREATE). (2020) (37)
Sofosbuvir: the final nail in the coffin for hepatitis C? (2013) (37)
Significance of the Caspase Family in Helicobacter pylori Induced Gastric Epithelial Apoptosis (2002) (36)
Isolated anti-HBV core phenotype in anti-HCV-positive patients is associated with hepatitis C virus replication. (2004) (36)
Seroprevalence of antibodies and antigens against hepatitis A–E viruses in refugees and asylum seekers in Germany in 2015 (2017) (36)
Treatment-related hemophagocytic lymphohistiocytosis secondary to checkpoint inhibition with nivolumab plus ipilimumab. (2018) (35)
TOX defines the degree of CD8+ T cell dysfunction in distinct phases of chronic HBV infection (2020) (35)
The German guideline for the management of hepatitis B virus infection: short version * (2008) (34)
Off-therapy response after nucleos(t)ide analogue withdrawal in patients with chronic hepatitis B: An international, multi-center, multi-ethnic cohort (RETRACT-B study). (2021) (34)
Rates of sustained virological response 12 weeks after the scheduled end of direct‐acting antiviral (DAA)‐based hepatitis C virus (HCV) therapy from the National German HCV registry: does HIV coinfection impair the response to DAA combination therapy? (2018) (34)
Effect of H. pylori on the Expression of TRAIL, FasL and their Receptor Subtypes in Human Gastric Epithelial Cells and their Role in Apoptosis (2004) (32)
Improvement of liver function parameters in advanced HCV-associated liver cirrhosis by IFN-free antiviral therapies (2015) (32)
Aktuelle Seroprävalenz, Impfstatus und prädiktiver Wert der Leberenzyme für Hepatitis B bei Flüchtlingen in Deutschland (2016) (31)
Systemic arterial blood pressure determines the therapeutic window of non‐selective beta blockers in decompensated cirrhosis (2019) (31)
Contrasting Timing of Virological Relapse After Discontinuation of Tenofovir or Entecavir in Hepatitis B e Antigen–Negative Patients (2018) (31)
Endothelial dysfunction contributes to severe COVID-19 in combination with dysregulated lymphocyte responses and cytokine networks (2021) (30)
Origin, prevalence and response to therapy of hepatitis C virus genotype 2k/1b chimeras. (2017) (30)
Mutations in Hepatitis D Virus Allow It to Escape Detection by CD8+ T Cells and Evolve at the Population Level (2019) (30)
Detection of low HCV viraemia by repeated HCV RNA testing predicts treatment failure to triple therapy with telaprevir (2014) (30)
Frequency, Private Specificity, and Cross-Reactivity of Preexisting Hepatitis C Virus (HCV)-Specific CD8+ T Cells in HCV-Seronegative Individuals: Implications for Vaccine Responses (2015) (30)
Fate of Goblet Cells in Experimental Colitis (2002) (29)
HEV-specific T-cell responses are associated with control of HEV infection (2012) (29)
Dose‐dependent impact of proton pump inhibitors on the clinical course of spontaneous bacterial peritonitis (2018) (28)
HCC Immune Surveillance and Antiviral Therapy of Hepatitis C Virus Infection (2018) (28)
What is new on HBsAg and other diagnostic markers in HBV infection? (2017) (27)
Addressing barriers to the prevention, diagnosis and treatment of hepatitis B and C in the face of persisting fiscal constraints in Europe: report from a high level conference (2016) (27)
Effect of peptide pools on effector functions of antigen-specific CD8+ T cells. (2009) (27)
Probability of HBsAg loss after nucleo(s)tide analogue withdrawal depends on HBV genotype and viral antigen levels. (2022) (26)
Hepatitis C virus core antigen testing in liver and kidney transplant recipients (2014) (26)
Prophylaxe, Diagnostik und Therapie der Hepatitis-C-Virus(HCV)-Infektion (2020) (25)
Applicability of Hepatitis C Virus RNA Viral Load Thresholds for 8-Week Treatments in Patients With Chronic Hepatitis C Virus Genotype 1 Infection. (2016) (25)
Eligibility and safety of the first interferon‐free therapy against hepatitis C in a real‐world setting (2015) (25)
Chronic hepatitis E virus infection beyond transplantation or human immunodeficiency virus infection (2014) (25)
Type I Interferon Elevates Co-Regulatory Receptor Expression on CMV- and EBV-Specific CD8 T Cells in Chronic Hepatitis C (2015) (25)
[Current seroprevalence, vaccination and predictive value of liver enzymes for hepatitis B among refugees in Germany]. (2016) (25)
Limited effectiveness and safety profile of protease inhibitor-based triple therapy against chronic hepatitis C in a real-world cohort with a high proportion of advanced liver disease (2014) (25)
Long-term changes in liver elasticity in hepatitis C virus-infected patients with sustained virologic response after treatment with direct-acting antivirals (2018) (24)
Cytomegalovirus-Driven Adaptive-Like Natural Killer Cell Expansions Are Unaffected by Concurrent Chronic Hepatitis Virus Infections (2017) (24)
MAIT Cells Are Enriched and Highly Functional in Ascites of Patients With Decompensated Liver Cirrhosis (2020) (24)
Prevalence of Hepatitis B, C, and D in Germany: Results From a Scoping Review (2020) (24)
Impact of HBsAg and HBcrAg levels on phenotype and function of HBV-specific T cells in patients with chronic hepatitis B virus infection (2021) (24)
S3-Leitlinie der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) zur Prophylaxe, Diagnostik und Therapie der Hepatitis-B-Virusinfektion – (AWMF-Register-Nr. 021-11) (2021) (23)
Intrahepatic long‐term persistence of parvovirus B19 and its role in chronic viral hepatitis (2009) (23)
Sofosbuvir monotherapy fails to achieve HEV RNA elimination in patients with chronic hepatitis E - The HepNet SofE pilot study. (2020) (23)
Current and future treatment of hepatitis C. (2001) (23)
NK Cells in Hepatitis C: Role in Disease Susceptibility and Therapy (2012) (23)
Human γδ T Cell Receptor Repertoires in Peripheral Blood Remain Stable Despite Clearance of Persistent Hepatitis C Virus Infection by Direct-Acting Antiviral Drug Therapy (2018) (22)
Fate and Function of Hepatitis-C-Virus-Specific T-Cells during Peginterferon-α2b therapy for Acute Hepatitis C (2006) (22)
HBsAg seroclearance with NUCs: rare but important (2014) (22)
A baseline tool for predicting response to peginterferon alfa‐2a in HBeAg‐positive patients with chronic hepatitis B (2018) (22)
Increased Immune Response Variability during Simultaneous Viral Coinfection Leads to Unpredictability in CD8 T Cell Immunity and Pathogenesis (2015) (22)
Cross‐genotype‐specific T‐cell responses in acute hepatitis E virus (HEV) infection (2016) (22)
Clinical Practice Guidelines of the European Association for the study of the Liver - Advancing methodology but preserving practicability. (2019) (22)
Ten‐year follow‐up of a randomized controlled clinical trial in chronic hepatitis delta (2020) (21)
The Third Signal Cytokine Interleukin 12 Rather Than Immune Checkpoint Inhibitors Contributes to the Functional Restoration of Hepatitis D Virus–Specific T Cells (2017) (21)
New viral biomarkers for Hepatitis B: Are we able to change practice? (2018) (21)
Impaired TRAIL‐dependent cytotoxicity of CD1c‐positive dendritic cells in chronic hepatitis C virus infection (2007) (21)
Polyethylene glycol–interferon: Current status in hepatitis C virus therapy (2002) (21)
Baseline risk factors determine lack of biochemical response after SVR in chronic hepatitis C patients treated with DAAs (2020) (20)
Management of HBV and HBV/HDV-Associated Liver Cirrhosis (2016) (20)
Impact of COVID-19 on the liver and on the care of patients with chronic liver disease, hepatobiliary cancer, and liver transplantation: An updated EASL position paper (2022) (19)
Adenosine and IFN‐α synergistically increase IFN‐γ production of human NK cells (2009) (19)
Variation of human mucin gene expression in gastric cancer cell lines and gastric mucous cell primary cultures. (1999) (19)
Assay for Hepatitis B Core-related Antigen Identify Patients With High Viral Load: Systematic Review and Meta-analysis of Individual Participant Data. (2020) (19)
Association Between Type 2 Diabetes Mellitus, HbA1c and the Risk for Spontaneous Bacterial Peritonitis in Patients with Decompensated Liver Cirrhosis and Ascites (2018) (18)
Hepatitis C virus infection from the perspective of heterologous immunity. (2016) (18)
Failure on voxilaprevir, velpatasvir, sofosbuvir and efficacy of rescue therapy. (2020) (18)
250 24 weeks of monotherapy with pegylated interferon alfa-2B in patients with acute hepatitis C (2003) (18)
Fulminant hepatic failure due to chemotherapy-induced hepatitis B reactivation: role of rituximab. (2010) (18)
Treatment of Naïve Patients with Chronic Hepatitis C Genotypes 2 and 3 with Pegylated Interferon Alpha and Ribavirin in a Real World Setting: Relevance for the New Era of DAA (2014) (18)
[Hepatitis E virus infection: a paradigm shift?]. (2010) (17)
PEG-IFN Alpha but Not Ribavirin Alters NK Cell Phenotype and Function in Patients with Chronic Hepatitis C (2014) (17)
Spontaneous clearance of chronic hepatitis C after liver transplantation: Are hepatitis C virus–specific T cell responses the clue? (2008) (17)
SAT-260-Global timing of hepatitis C virus elimination: estimating the year countries will achieve the World Health Organization elimination targets (2019) (17)
Hepatitis: No cure for hepatitis B and D without targeting integrated viral DNA? (2018) (17)
[4 years of direct-acting antivirals (DAAs) in the German Hepatitis C-Registry (DHC-R)]. (2019) (17)
Interferon-free cure of chronic Hepatitis C is associated with weight gain during long-term follow-up (2017) (17)
Improved immune status corresponds with long-term decline of quantitative serum hepatitis B surface antigen in HBV/HIV co-infected patients. (2012) (17)
Hepatitis C: therapeutic perspectives. (2001) (17)
Donor T cells primed on leukemia lysate-pulsed recipient APCs mediate strong graft-versus-leukemia effects across MHC barriers in full chimeras. (2009) (17)
Response to discontinuation of long-term nucleos(t)ide analogue treatment in HBeAg negative patients: Results of the Stop-NUC trial (2020) (16)
S1179 Bulevirtide Monotherapy at Low and High Dose in Patients With Chronic Hepatitis Delta: 24-Week Interim Data of the Phase 3 MYR301 Study (2022) (16)
Therapeutic vaccination of chronic hepatitis B patients with ABX203 (NASVAC) to prevent relapse after stopping NUCs: contrasting timing rebound between tenofovir and entecavir (2017) (16)
Frequency of Potential Drug–Drug Interactions in the Changing Field of HCV Therapy (2020) (16)
1047 EARLY VERSUS DELAYED TREATMENT OF ACUTE HEPATITIS C: THE GERMAN HEP-NET ACUTE HCV-III STUDY – A RANDOMIZED CONTROLLED TRIAL (2009) (15)
Article Commentary: ImPortance of IP-10 in Hepatitis B (2016) (15)
EASL Clinical Practice Guidelines on haemochromatosis. (2022) (14)
Six weeks of sofosbuvir/ledipasvir (SOF/LDV) are sufficient to treat acute hepatitis C virus genotype 1 monoinfection: The HepNet Acute HCV IV Study (2016) (14)
Residual low HDV viraemia is associated HDV RNA relapse after PEG‐IFNa‐based antiviral treatment of hepatitis delta: Results from the HIDIT‐II study (2020) (14)
Resistance to Vaccinia Virus Is Less Dependent on TNF under Conditions of Heterologous Immunity1 (2009) (14)
Hepatitis E virus ORF 1 induces proliferative and functional T‐cell responses in patients with ongoing and resolved hepatitis E (2018) (13)
Detailed stratified GWAS analysis for severe COVID-19 in four European populations (2022) (13)
New susceptibility loci for severe COVID-19 by detailed GWAS analysis in European populations (2021) (13)
Long-Lasting Imprint in the Soluble Inflammatory Milieu Despite Early Treatment of Acute Symptomatic Hepatitis C (2021) (13)
Incremental value of HBcrAg to classify 1582 HBeAg‐negative individuals in chronic infection without liver disease or hepatitis (2021) (13)
O119 : Stopping tenofovir disoproxil fumarate (TDF) treatment after long term virologic suppression in HBeAg-negative CHB: Week 48 interim results from an ongoing randomized, controlled trial (“finite CHB”) (2015) (13)
Efficacy and safety of bulevirtide monotherapy given at 2 mg or 10 mg dose level once daily for treatment of chronic hepatitis delta: week 48 primary end point results from a phase 3 randomized, multicenter, parallel design study (2022) (12)
Coronavirus disease 2019 vaccination in transplant recipients (2021) (12)
Safety and efficacy of bulevirtide in combination with tenofovir disoproxil fumarate in patients with hepatitis B virus and hepatitis D virus coinfection (MYR202): a multicentre, randomised, parallel-group, open-label, phase 2 trial. (2022) (12)
Stopping Tenofovir Disoproxil Fumarate (TDF) treatment after long term virologic suppression in HBeAg-negative CHB: Week 48 interim results from an ongoing randomized, controlled trial („FINITE CHB“) (2015) (12)
Commutability and concordance of four hepatitis B virus DNA assays in an international multicenter study (2017) (12)
Sustained impact of nosocomial-acquired spontaneous bacterial peritonitis in different stages of decompensated liver cirrhosis (2019) (12)
Hepatitis C reference viruses highlight potent antibody responses and diverse viral functional interactions with neutralising antibodies (2020) (12)
Present and future therapy for hepatitis C virus (2006) (11)
Frequency, characteristics and impact of multiple consecutive nosocomial infections in patients with decompensated liver cirrhosis and ascites (2020) (11)
Real‐world effect of ribavirin on quality of life in HCV‐infected patients receiving interferon‐free treatment (2018) (11)
Systemic inflammation and immune cell phenotypes are associated with neuro‐psychiatric symptoms in patients with chronic inflammatory liver diseases (2018) (11)
Morphological and molecular characterization of human gastric mucous cells in long-term primary culture (1998) (11)
Therapie der chronischen Hepatitis C mit PEG-Interferon alpha-2b und Ribavirin: 24 Wochen Behandlung sind ausreichend bei HCV-Genotyp 2 und 3 (2003) (11)
Expertenempfehlungen zur Triple-Therapie der HCV-Infektion mit Boceprevir und Telaprevir (2012) (11)
Eradication of Chronic HCV Infection: Improvement of Dysbiosis Only in Patients Without Liver Cirrhosis (2021) (11)
Letter: can persisting liver stiffness indicate increased risk of hepatocellular cell carcinoma after successful anti‐HCV therapy? – authors’ reply (2016) (11)
Defining Virus-specific CD8+ TCR Repertoires for Therapeutic Regeneration of T Cells against Chronic Hepatitis E. (2019) (11)
DAA-Induced HCV Clearance does not Restore the Altered Cytokine and Chemokine Milieu in Patients with Chronic Hepatitis C (2016) (10)
Soluble immune markers in the different phases of chronic hepatitis B virus infection (2019) (10)
[Costs of guideline-based treatment of hepatitis B patients in Germany]. (2012) (10)
LBO-04-Efficacy and safety of sofosbuvir monotherapy in patients with chronic hepatitis E-The HepNet SofE pilot study (2019) (10)
New kids on the block—step by step to an ideal HCV therapy (2015) (10)
Pilot Study Using Machine Learning to Identify Immune Profiles for the Prediction of Early Virological Relapse After Stopping Nucleos(t)ide Analogues in HBeAg‐Negative CHB (2020) (9)
Hepatitis B – Ein Ausblick auf aktualisierte Leitlinien (2018) (9)
UEG framework for the development of high-quality clinical guidelines (2020) (9)
The impact of proton pump inhibitors on the intestinal microbiota in chronic hepatitis C patients (2018) (9)
Only partial improvement in health‐related quality of life after treatment of chronic hepatitis C virus infection with direct acting antivirals in a real‐world setting—results from the German Hepatitis C‐Registry (DHC‐R) (2021) (9)
Letter: a 5‐year long‐term follow‐up study after DAA treatment confirms a reduced HCC risk in a central European cohort of HCV patients with liver cirrhosis (2020) (9)
and weight-based ribavirin in patients with genotype (2011) (8)
Going beyond clinical routine in SARS-CoV-2 antibody testing - A multiplex corona virus antibody test for the evaluation of cross-reactivity to endemic coronavirus antigens (2020) (8)
[German guidelines on diagnosis and therapy of hepatitis B]. (2007) (8)
Early versus delayed treatment of acute hepatitis C: Final results of the randomized controlled German HEP-NET acute HCV-III study (2012) (8)
Altered effector functions of NK cells in chronic hepatitis C are associated with IFNL3 polymorphism (2015) (8)
Hepatitis E Virus (HEV)-Specific T Cell Receptor Cross-Recognition: Implications for Immunotherapy (2019) (8)
Hepatitis-assoziierte Kryoglobulinämie (2008) (8)
Experimental Drugs for the Treatment of Hepatitis D (2021) (8)
Protected or not protected, that is the question - First data on COVID-19 vaccine responses in patients with NAFLD and liver transplant recipients (2021) (8)
Updated epidemiology of hepatitis C virus infections and implications for hepatitis C virus elimination in Germany (2022) (7)
When a respiratory pathogen turns to the skin: cutaneous tuberculosis in a lung transplant patient (2015) (7)
[Knowledge and management of hepatitis B virus infected patients in Germany]. (2012) (7)
Safety and feasibility of transjugular intrahepatic portosystemic shunt in elderly patients with liver cirrhosis and refractory ascites (2020) (7)
Treatment of acute hepatitis C-how to explain the differences? (2006) (7)
Freiburg index of post-TIPS survival (FIPS) a valid prognostic score in patients with cirrhosis but also an advisor against TIPS? (2021) (7)
Daclatasvir plus Sofosbuvir with or without Ribavirin for the Treatment of Chronic HCV Infection in Patients with Decompensated Cirrhosis: Results of a European Multicentre Compassionate Use Program (2016) (7)
Quantitation of large, middle and small hepatitis B surface proteins in HBeAg‐positive patients treated with peginterferon alfa‐2a (2019) (7)
Treatment duration in acute hepatitis C: The issue is not solved yet (2006) (7)
Symptoms of anxiety and depression are frequent in patients with acute hepatitis C and are not associated with disease severity (2015) (7)
Daclatasvir plus Sofosbuvir with or without Ribavirin in patients infected with HCV genotype 3: Interim results of a multicenter compassionate use program in Europe (2015) (7)
Reliable quantification of plasma HDV RNA is of paramount importance for treatment monitoring: A European multicenter study. (2021) (7)
Identification of Novel Population-Specific Cell Subsets in Chinese Ulcerative Colitis Patients Using Single-Cell RNA Sequencing (2021) (7)
Glecaprevir/pibrentasvir for 8 weeks in patients with compensated cirrhosis: Safety and effectiveness data from the German Hepatitis C‐Registry (2021) (7)
How to interpret borderline HCV antibody test results: a comparative study investigating four different anti-HCV assays. (2014) (7)
Deutsches Hepatitis C-Register (DHC-R) – eine Zwischenbilanz 4 Jahre nach Zulassung direkt antiviraler Substanzen (DAAs) (2019) (6)
Imprint of unconventional T‐cell response in acute hepatitis C persists despite successful early antiviral treatment (2021) (6)
Pneumococcal meningitis during antiviral treatment with interferon and ribavirin in a splenectomized patient with chronic hepatitis C - do not miss vaccination before starting therapy. (2008) (6)
Different kinetics of liver stiffness using shear wave elastography in patients with chronic hepatitis C infection treated with interferon-free regimens (2019) (6)
Neue direkt antivirale Medikamente zur Behandlung der chronischen Hepatitis C 2014 (2014) (6)
HBcrAg Levels Are Associated With Virological Response to Treatment With Interferon in Patients With Hepatitis Delta (2021) (6)
Longitudinal Tracking of Immune Responses in COVID-19 Convalescents Reveals Absence of Neutralization Activity Against Omicron and Staggered Impairment to Other SARS-CoV-2 Variants of Concern (2022) (6)
Treatment Extension of Pegylated Interferon Alpha and Ribavirin Does Not Improve SVR in Patients with Genotypes 2/3 without Rapid Virological Response (OPTEX Trial): A Prospective, Randomized, Two-Arm, Multicentre Phase IV Clinical Trial (2015) (6)
48 EARLY VERSUS DELAYED TREATMENT OF ACUTE HEPATITIS C: FINAL RESULTS OF THE RANDOMIZED CONTROLLED GERMAN HEP-NET ACUTE HCV-III STUDY (2012) (6)
Treatment of acute hepatitis C infection with interferon-alfa 2b monotherapy prevents development of chronic HCV infection (2001) (6)
Hepatitis C: individualised medicine versus one pill fits all. (2016) (5)
Case Report: Convalescent Plasma Therapy Induced Anti-SARS-CoV-2 T Cell Expansion, NK Cell Maturation and Virus Clearance in a B Cell Deficient Patient After CD19 CAR T Cell Therapy (2021) (5)
333 KINETICS OF HCV CORE ANTIGEN DURING ANTIVIRAL TREATMENT OF ACUTE AND CHRONIC HEPATITIS C AS DETERMINED BY A NOVEL CHEMILUMINESCENT MICROPARTICLE IMMUNOASSAY (2009) (5)
The hepatitis E virus: a likely cause of extrahepatic diseases! (2016) (5)
A Genotype-Specific Baseline Score to Predict Response at 48 Weeks Post-Treatment to Peginterferon Alfa-2a in Patients with HBeAg-Negative Chronic Hepatitis B (2016) (5)
Hepatitis C virus-specific T cell responses against conserved regions in recovered patients. (2009) (5)
Role of soluble inflammatory mediators and different immune cell populations in early control of symptomatic acute hepatitis C virus infection (2018) (5)
Daclatasvir plus Sofosbuvir with or without Ribavirin for Treatment of Chronic HCV Infection in Patients with Advanced Liver Disease: Results of a European Compassionate use Program (2016) (5)
S1-Leitlinie zur Versorgung von Lebertransplantierten während der COVID-19-Pandemie (2021) (5)
Comprehensive phenotyping of regulatory T cells after liver transplantation (2015) (5)
THU-188-Retreatment with sofosbuvir/velpatasvir/voxilaprevir in patients with chronic hepatitis C virus infection and prior DAA failure: An analysis from the German hepatitis C registry (DHC-R) (2019) (5)
Chronic Viral Liver Diseases: Approaching the Liver Using T Cell Receptor-Mediated Gene Technologies (2020) (5)
Stomach reduction or gastric bypass as risk factor for treatment failure after DAA therapy for hepatitis C? (2017) (5)
Effectiveness of Peginterferon Alfa-2a Therapy in HBeAg-Positive and HBeAg-Negative Patients with Chronic Hepatitis B: Final Results 3 Years Post-Treatment of the Prospective, Global, Observational S-Collate Study (2016) (5)
Immunological, virological and clinical long-term follow-up after interferon therapy of acute hepatitis C infection (2003) (4)
Challenges in warranting access to prophylaxis and therapy for hepatitis B virus infection (2017) (4)
770 STOPPING LONG-TERM NUCLEOS(T)IDE ANALOGUE THERAPY BEFORE HBsAg LOSS IN HBeAg NEGATIVE CHB PATIENTS: FOLLOW-UP OF LONG TERM RESPONDERS (2013) (4)
Identification of Keratin 23 as a Hepatitis C Virus-Induced Host Factor in the Human Liver (2019) (4)
Glecaprevir/Pibrentasvir + Sofosbuvir + Ribavirin als Reserveregime nach Sofosbuvir + Velpatasvir + Voxilaprevir Re-Therapieversagen (2021) (4)
[Treatment of chronic hepatitis C with PEG-interferon alpha-2b and ribavirin: 24 weeks of therapy are sufficient for HCV genotype 2 and 3]. (2003) (4)
144 REDUCED DOSE AND DURATION OF PEGINTERFERON ALFA-2B + WEIGHT-BASED RIBAVIRIN IN EUROPEAN AND ASIAN GENOTYPE 2 AND 3 CHRONIC HEPATITIS C PATIENTS (REDD 2/3 TRIAL) (2009) (4)
PD-L1 Checkpoint Inhibition Narrows the Antigen-Specific T Cell Receptor Repertoire in Chronic Lymphocytic Choriomeningitis Virus Infection (2020) (4)
Reappearance of Effector T Cells Predicts Successful Recovery from COVID-19 (2020) (4)
Weight Gain after IFN-Free Cure of Chronic Hepatitis C: A Potential Concern? (2016) (4)
Long-term follow-up after IFN-free therapy of advanced HCV-associated liver cirrhosis: continued improvement of liver function parameters – Results from the German Hepatitis C-Registry (DHC-R) (2017) (4)
[New direct-acting antiviral agents for the treatment of chronic hepatitis C in 2014]. (2014) (4)
Safety of Direct-Acting Antivirals-Based Therapy for the Treatment of Patients with Chronic Hepatitis C Virus Infection and Cirrhosis: Results from an International Multicenter Cohort Study (2016) (4)
New approaches and therapeutic modalities for the treatment of patients with chronic hepatitis C. (2005) (4)
Sofosbuvir, velpatasvir, and voxilaprevir for patients with failure of previous direct-acting antiviral therapy for chronic hepatitis C: Results from the German Hepatitis C-Registry (DHC-R) (2020) (4)
Towards eradication of HBV: Treatment approaches and status of clinical trials. (2021) (4)
Clinical impact of pharmacokinetic interactions between the HCV protease inhibitor simeprevir and frequently used concomitant medications (2018) (3)
Performance and Value of IFN-Lambda3 and IFN-Lambda4 Genotyping in Patients with Chronic Hepatitis C (CHC) Genotype 2/3 in a Real World Setting (2015) (3)
A transient early HBV‐DNA increase during PEG‐IFNα therapy of hepatitis D indicates loss of infected cells and is associated with HDV‐RNA and HBsAg reduction (2020) (3)
OMIP‐084: 28‐color full spectrum flow cytometry panel for the comprehensive analysis of human γδ T cells (2022) (3)
A genotype-specific baseline score predicts post-treatment response to peginterferon alfa-2a in hepatitis B e antigen-negative chronic hepatitis B (2018) (3)
Hepatitis C in Deutschland: (2015) (3)
Reverse Inflammaging: Long-term effects of HCV cure on biological age (2022) (3)
855 A CLINICAL TRIAL EVALUATING LOW HCVRNA VIREMIA IN PATIENTS TREATED WITH TRIPLE THERAPY REGIMENS: IMPLICATIONS FOR PATIENT MANAGEMENT USING DIFFERENT ASSAYS IN CLINICAL PRACTICE (2013) (3)
The curing regimens of HCV: A SWOT analysis (2022) (3)
Addition of pegylated interferon alfa-2a to an ongoing nucleos(t) ide treatment accelerates decrease of HBs-antigen levels in patients with chronic hepatitis B: Results from the PADD-ON study (2018) (3)
The impact of hepatitis B surface antigen on natural killer cells in patients with chronic hepatitis B virus infection (2021) (3)
1159 SERUM ZINC BUT NOT SERUM VITAMIN D LEVELS ARE ASSOCIATED WITH DISEASE SEVERITY AND TREATMENT RESPONSE IN CHRONIC HEPATITIS C VIRUS INFECTION (2011) (3)
Future trends in hepatitis C therapy (2006) (3)
Editorial: which factors influence HBsAg levels in HBV‐infected patients? (2020) (3)
FRI-131-Impact of HBsAg level on cellular immune responses in HBeAg negative patients with chronic hepatitis B virus infection (2019) (3)
Safety and Effectiveness Using 8 Weeks of Glecaprevir/Pibrentasvir in HCV-Infected Treatment-Naïve Patients with Compensated Cirrhosis: The CREST Study (2022) (3)
Significant compartment‐specific impact of different RNA extraction methods and PCR assays on the sensitivity of hepatitis E virus detection (2021) (3)
Reaching the Unreachable: Strategies for HCV Eradication in Patients With Refractory Opioid Addiction—A Real-world Experience (2021) (3)
Treatment of chronic hepatitis C with consensus interferon in relapsers and non-responders to interferon-based therapy. (2007) (3)
Safety and Efficacy of IFN- Free Antiviral Therapies in Advanced HCV- Associated Liver Cirrhosis: Results from the German Hepatitis C-Registry (DHC-R) (2016) (3)
Multi-Omics Integration Reveals Only Minor Long-Term Molecular and Functional Sequelae in Immune Cells of Individuals Recovered From COVID-19 (2022) (3)
IgG, a novel predictor for acute-on-chronic liver failure and survival in patients with decompensated cirrhosis? (2021) (3)
Six weeks of Sofosbuvir/Ledipasvir treatment of acute hepatitis C Virus genotype 1 monoinfection: Final results of the German HepNet Acute HCV IV Study (2016) (3)
Home‐based, tunnelled peritoneal drainage system as an alternative treatment option for patients with refractory ascites (2022) (3)
HBV‐RNA Co‐amplification May Influence HBV DNA Viral Load Determination (2020) (3)
Liver stiffness across different chronic liver disease under therapy with statin in a real life cohort. (2020) (3)
Embedding T cells in the matrix (2004) (3)
Impact of HBV coinfection on hepatitis C virus infection: analysis of 3054 anti HCV-positive patients (2001) (3)
PS-184-Real-world effectiveness and safety of glecaprevir/pibrentasvir in adults with chronic hepatitis C virus infection: A meta-analysis (2019) (3)
Pegylated interferons in combination with ribavirin for the treatment of chronic hepatitis C (2003) (3)
[Current Guidelines for treatment of hepatitis B. Correct diagnosis is the prerequisite.]. (2011) (3)
857 TRIPLE THERAPY FOR HEPATITIS C VIRUS (HCV) INFECTION IN PATIENTS WITH COMPENSATED LIVER CIRRHOSIS: LESSONS LEARNED FROM THE FIRST REAL-WORLD EXPERIENCE (2013) (2)
Distinct Immune Imprints of Post–Liver Transplantation Hepatitis C Persist Despite Viral Clearance (2021) (2)
Sofosbuvir for the treatment of patients with genotype 2 or 3 chronic hepatitis C virus infection (2014) (2)
[Hepatitis C in Germany: an analysis of statutory sickness funds claims data]. (2015) (2)
Treatment of HCV Genotype 2 with Sofosbuvir and Ribavirin Results in Low SVR Rates ina Real World Cohort (German Hepatitis C-Registry, DHC-R) (2016) (2)
[PEG-interferons: significance for the treatment of viral hepatitis B and C]. (2001) (2)
GS-07-Real-world safety, effectiveness, and patient-reported outcomes in patients with chronic hepatitis C virus infection treated with glecaprevir/pibrentasvir: Data from the German Hepatitis C-Registry (2019) (2)
Bulevirtide treatment of hepatitis D in Germany: multicentre real-world experience (2022) (2)
Elevated liver enzymes predict morbidity and mortality despite antiviral cure in patients with chronic hepatitis C: Data from the German Hepatitis C‐Registry (2022) (2)
Interferon-free therapy of chronic hepatitis C does not change the short-term risk for de novo hepatocellular carcinomas in patients with liver cirrhosis (2017) (2)
Präsidentenposter: Early versus delayed treatment of acute hepatitis C: The German HEP-NET acute HCV-III study – a randomized controlled trial (2009) (2)
Late-breaking abstracts (2007) (2)
High real-world effectiveness of elbasvir/grazoprevir (EBR/GZR) in PWID on opioid substitution therapy with HCV genotype 1 (GT1) infection: results from the German Hepatitis C Registry (DHC-R) (2019) (2)
S1-Leitlinie zur Versorgung von Lebertransplantierten während der COVID-19-Pandemie – AWMF-Registernummer: 021-031 – Stand 15. Juni 2022 (2022) (2)
Re-Therapie von DAA-Versagern mit Sofosbuvir/Velpatasvir/Voxilaprevir – Ergebnisse aus dem Deutschen Hepatitis C-Register (DHC-R) (2018) (2)
A tool to measure the impact of inaction towards elimination of hepatitis C virus: A case study in Germany (2018) (2)
Impact of the COVID-19 pandemic on patients with liver cirrhosis—the experience of a tertiary center in Germany (2021) (2)
Prävention der Virushepatitis A bis E (2011) (2)
Increasing Number of Individuals Receiving Hepatitis B nucleos(t)ide Analogs Therapy in Germany, 2008–2019 (2021) (2)
P0877 : HCVRNA levels assessed at early stages of sofosbuvir/ribavirin dual therapy identify relapse patients (2015) (2)
Final analysis of the international observational S-Collate study of peginterferon alfa-2a in patients with chronic hepatitis B (2020) (2)
S1-Leitlinie zur Versorgung von Lebertransplantierten während der COVID-19-Pandemie – AWMF-Register Nr. 021-031 – Stand: 07.01.21 (2021) (2)
Leitliniengerechte Therapie der Hepatitis B. Korrekte Indikationsstellung ist die Voraussetzung (2011) (2)
Neue Interferon-freie Therapien für Patienten mit chronischer Hepatitis C Genotyp 1 (2014) (2)
Kosten einer leitliniengerechten Versorgung von Hepatitis-B-Patienten in Deutschland (2012) (2)
Lonafarnib—A new member of the Delta Force? (2022) (2)
Differential expression of the adenosine receptor subtypes in human gastric mucosa and cancer cells (2000) (2)
A Genotype-Specific Baseline Score to Predict Post-Treatment Response to Peginterferon Alfa-2a in HBeAg-Positive Patients with Hepatitis B Virus Genotype B or C Infection (2016) (2)
364 HBsAg SERUM LEVELS ARE ASSOCIATED WITH THE PHASE OF HBV-INFECTION (2009) (2)
1232 INCREASED HEV SEROPREVALENCE IN PATIENTS WITH AUTOIMMUNE HEPATITIS (2013) (2)
[Entecavir - options and obstacles of an effective treatment for chronic hepatitis B]. (2010) (2)
Long-term changes of liver elasticity in HVC-infected patients with SVR after treatment with direct-acting antivirals (2018) (2)
Stopping long-term NUCs therapy before HBsAg loss in HBeAg negative patients: follow-up of long-term responders (2013) (2)
Making sense of muscle fatigue and liver lesions. (2007) (2)
Performance of Roche qualitative HEV assay on the cobas 6800 platform for quantitative measurement of HEV RNA. (2020) (2)
Delayed early HCV RNA response during IFN-free therapy with sofosbuvir in interferon-ineligible patients with advanced cirrhosis (2015) (2)
Fulminant parvovirus B19 myocarditis after chemotherapy: full recovery after antiviral therapy with tenofovir (2021) (2)
Interferon-free cure of hepatitis C virus infection does alter the soluble inflammatory milieu which could affect hepatocellular carcinoma surveillance by CD8+ T cells in patients with liver cirrhosis (2017) (2)
Inflammatory patterns in plasma associate with hepatocellular carcinoma development in cured hepatitis C cirrhotic patients (2020) (2)
PS-081-Systemic arterial blood pressure determines the therapeutic window of non selective betablockers in patients with decompensated liver cirrhosis (2019) (2)
375 HEPATITIS B SURFACE ANTIGEN CONCENTRATION IN HEPATITIS B/C CO-INFECTION (2009) (2)
Integrated efficacy analysis of 24-week data from two phase 2 and one phase 3 clinical trials of bulevirtide monotherapy given at 2 mg or 10 mg dose level for treatment of chronic hepatitis delta (2022) (2)
THU-145-High real-world effectiveness of elbasvir/grazoprevir in a HCV genotype 1 population with a migration background and predominant subtype 1b infection: Results from the German hepatitis C registry (DHC-R) (2019) (1)
711 SERUM CYTOKINE LEVELS DURING PEG-IFNA-2a +/− ADEFOVIR TREATMENT OF DELTA HEPATITIS: RESULTS FROM THE HEP-NET/INTERNATIONAL HIDIT-1 STUDY (2008) (1)
Nosocomial infections in female compared with male patients with decompensated liver cirrhosis (2022) (1)
[Personalized treatment of viral hepatitis of the present and the future : Hepatitis B, C, delta, and E]. (2017) (1)
Bile acid increase during bulevirtide treatment of hepatitis D is not associated with a decline in HDV RNA. (2023) (1)
Differential relapse patterns after discontinuation of entecavir vs tenofovir disoproxil fumarate in chronic hepatitis B. (2022) (1)
Dominance of HCV in HBV/HCV co-infected patients is associated with lower quantitative HBsAg and higher serum IP-10 levels (2013) (1)
358 COMPARING THE LONG-TERM OUTCOME OF HEPATITIS DELTA AND HBV MONOINFECTION: IS HDV-INFECTION REALLY WORSE? (2011) (1)
[Paradigmatic change in treatment of viral hepatitides]. (2012) (1)
Kinetics and predictive value of HBcrAg, HBV RNA and anti‐HBc during bulevirtide treatment of chronic HDV‐infected patients (2023) (1)
Impact of HBsAg on HBV-specific immune responses in HBeAg negative patients with chronic hepatitis B (2019) (1)
P1109 OVERTREATMENT OF PATIENTS WITH CHRONIC HEPATITIS C (CHC) GENOTYPE 2/3 WITH LOW BASELINE VIRAL LOAD AND RVR: EXPERIENCES IN A REAL WORLD SETTING (2014) (1)
565 RIBAVIRIN TREATMENT OF HEV INFECTION IN IMMUNOCOMPETENT AND IMMUNOCOMPROMISED PATIENTS: WHICH PATIENTS NEED ANTIVIRAL THERAPY? (2012) (1)
Antimicrobial resistance in patients with decompensated liver cirrhosis and bacterial infections in a tertiary center in Northern Germany (2021) (1)
Spezifische Infektionen bei Organtransplantationen (2016) (1)
Proinflammatory cytokines differnetially affect mucin expression in LS180 cells (1998) (1)
Identification of patients with compensated cirrhosis who can safely use protease inhibitor-based therapy for HCV infection (2020) (1)
THU-178-Drug-drug interactions in HCV therapy: Still relevant for clinical practice? (2019) (1)
Treatment of Patients with Hepatitis C Virus (HCV) Genotype 3 Infection in the Era of Direct Acting Antivirals (DAA): Data from the German Hepatitis C-Registry (DHC-R) (2016) (1)
Therapie der Hepatitis-C-Infektion (2001) (1)
Interruption of nucleos(t)ide analogue therapy in HBeAg negative chronic hepatitis B – A new concept to achieve HBsAg decline? (2015) (1)
Early monotherapy with pegylated interferon alfa–2b for acute hepatitis C infection: Final Results of the German HEP-NET Acute HCV II Study (2005) (1)
Diagnostik und Therapie der Hepatitis (2009) (1)
HBV RNA levels are associated with virological response to treatment with pegylated interferon alpha in patients with chronic hepatitis D virus infection (2022) (1)
Entecavir - Möglichkeiten und Grenzen einer effektiven Therapie der chronischen Hepatitis B (2010) (1)
Neue Behandlungsansätze in der Therapie der Hepatitis C (2007) (1)
Durability of HBsAg loss during or after antiviral treatment in a predominantly middle European collective (2018) (1)
Differenzielle Muzinexpression im Gastrointestinaltrakt (2001) (1)
Low Serum Cholinesterase Identifies Patients With Worse Outcome and Increased Mortality After TIPS (2021) (1)
Veränderungen der Laboranforderungen zur Diagnostik von Virushepatitiden unter Fortentwicklung von Leitlinien (2016) (1)
Partially Restored T Cell Responses in HBEAG-Negative Chronic Patients after Stopping NA therapy (2016) (1)
Clinical significance of drug-drug interactions during HCV therapy with sofosbuvir and simeprevir in comparison to first wave protease inhibitors (2015) (1)
Evidence-Based Approach to Stopping Oral Antiviral Therapy in Chronic HBV (2019) (1)
[Differential mucin expression in the gastrointestinal tract]. (2001) (1)
Late presentation of chronic hepatitis C patients in the era of direct‐acting antivirals—Data from the German Hepatitis C‐Registry (2021) (1)
P667 HEPATITIS B CORE-RELATED ANTIGEN (HBcrAg) LEVELS IN THE NATURAL HISTORY OF HEPATITIS B INFECTION IN A LARGE EUROPEAN COHORT (2014) (1)
313 DYNAMIC FLUCTUATION OF VIROLOGICAL MARKERS DURING THE NATURAL COURSE OF HEPATITIS DELTA (2010) (1)
Successful retreatment of a patient with chronic hepatitis C genotype 2k/1b virus with ombitasvir/paritaprevir/ritonavir plus dasabuvir (2017) (1)
Plasma and ascites pharmacokinetic of meropenem in patients with decompensated liver cirrhosis and spontaneous bacterial peritonitis. (2021) (1)
[One pill for all HCV-genotypes?]. (2016) (1)
P043: Injecting drug users (IDUs) are prone to Hepatitis B because of the high risk behaviour. Hepatitis B can be prevented through vaccines but the IDUs and their sexual partners from Kathmandu, Nepal are not getting preventive hepatitis B vaccinations (2015) (1)
Kinetics of cellular immune responses during the early phase of IFN + ribavirin therapy of chronic hepatitis C infection (2001) (1)
Metamizole-Associated Risks in Decompensated Hepatic Cirrhosis. (2022) (1)
Triple therapy for hepatitis C virus (HCV) infection: Eligibility, safety and efficacy in a real world setting (2013) (1)
Low anti‐HBc levels are associated with lower risk of virological relapse after nucleos(t)ide analogue cessation in HBe antigen‐negative patients (2022) (1)
Baseline bile acid levels but not bile acid increases during bulevirtide treatment of hepatitis D are associated with HDV RNA decline (2022) (1)
Use of the 6 million viral load cut-off to guide treatment duration with ledipasvir/sofosbuvir in patients with chronic hepatitis C virus genotype 1 infection: results from the German Hepatitis C-Registry (DHC-R) (2017) (1)
Reply to: "Serum HBsAg kinetics in clinical prediction". (2017) (1)
Hepatocellular carcinoma and hepatitis B virus reactivation - a preventable condition not to be missed. (2022) (1)
Extrahepatic Manifestations of Hepatitis C Virus Infection (2013) (1)
HCC and HBV reactivation—A preventable condition not to be missed (2022) (1)
Impact of CD4+ blood cell count and HIV viral load on treatment response with direct acting antivirals in HIV and HCV coinfected patients: insights from the German Hepatitis C-Registry (2018) (1)
[Influence of a spontaneous bacterial peritonitis, nosocomial infections and acute-on-chronic liver failure on treatment revenues in patients with decompensated cirrhosis in Germany]. (2020) (1)
FRI-175-Frequency, severity and impact of Peg-IFNa-associated flares in HDV infection: Results from the HIDIT-II study (2019) (1)
Regulation of cytosolic free calcium concentration by extracellular nucleotides in human hepatocytes. (1999) (1)
Detection of low HCV viremia by repeated HCV RNA testing predicts treatment failure to triple therapy with telaprevir (2013) (1)
Clinical Virology: Diagnosis and Virologic Monitoring (2016) (1)
Add on Interferon-Alpha-2a for the treatment of hbeag negative Hepatitis B patients receiving effective nucleos (t)ide therapy: interim results of the prospective multicentre padd-on trial (2016) (1)
Altered and allele-specific open chromatin landscape reveals epigenetic and genetic regulators of innate immunity in COVID-19 (2022) (1)
[Laboratory requirements to diagnose viral hepatitis under the development of guidelines]. (2016) (1)
Induction of innate and adaptive immune responses after stopping NA therapy in HBeAg negative chronic hepatitis B (2015) (1)
CD103 identifies an ascites-resident NK cell subset with reduced effector capacity that originates in the intestine (2023) (0)
P071: Viral hepatitis A, B and C in an Afro‐Brazilian community ten years after the first epidemiological and molecular survey (2015) (0)
The differential phenotype and functionality of CMV- and EBV-specific CD8 T cells in patients with chronic hepatitis C is associated with an altered plasma cytokine milieu (2015) (0)
How Good Is Hepatitis B Surface Antigen Kinetics Informing Strategy to Stop Antiviral Therapy ? (2017) (0)
346 COMPRISED FUNCTION OF NATURAL KILLER CELLS IN ACUTE AND CHRONIC VIRAL HEPATITIS (2013) (0)
Immune escape pathways from the HBV core18-27 CD8 T cell response are driven by individual HLA class I alleles (2022) (0)
Prognostic serum biomarkers for graft survival after liver transplantation in hepatitis C patients (2013) (0)
The Addition of Ribavirin is Associated with a Significantly Reduced Quality of Life in Patients Treated with IFN-Free Direct-Acting Antiviral Therapy (2016) (0)
Klinischer und virologischer Verlauf einer akuten Hepatits A bei Patienten mit Hepatitis C: Geringes Risiko für eine fulminante Hepatitis und Suppression der HCV-Replikation (2006) (0)
Hep-Net (2002) (0)
Characterization of lymphocyte subsets in ascites during spontaneous bacterial peritonitis: MAIT cells show the strongest increase (2020) (0)
Increased natural killer cell function after structured interruption of long-term nucleos(t)ide analogue therapy is associated with active hepatitis (2017) (0)
P121: Comparative proteomic analysis reveals alterations of Sec61 ER‐translocon at the acute and chronic stages of hepatitis C virus infection in a cell‐based reporter system (2015) (0)
Impact of non-selective beta-blockers on survival and liver-related complications after TIPS-Insertion (2022) (0)
Hepatitis B Seroprevalence and Immunization Status of Refugees Seeking Asylum in Germany in the Current Middle-East Crisis (2016) (0)
SAT-112-Each additional infection significantly increases mortality in patients with decompensated liver cirrhosis (2019) (0)
High effectiveness of elbasvir/grazoprevir (EBR/GZR) treatment in patients with HCV genotype 1a (GT1a) infection in German real-world: results from the German Hepatitis C Registry (DHC-R) (2019) (0)
651 VIROLOGICAL AND CLINICAL PATTERNS OF DELTA HEPATITIS IN CENTRAL EUROPE: A SINGLE CENTER EXPERIENCE WITH 255 PATIENTS (2008) (0)
Subject Index Vol. 30, Suppl. 1, 2012 (2012) (0)
729 ROLE OF BMI, AGE AND SEX FOR DISEASE SEVERITY IN ACUTE HEPATITIS C: ANALYSIS OF 254 PATIENTS FROM THE GERMAN HEP-NET ACUTE HCV COHORT (2008) (0)
P698 CLINICAL OUTCOME AFTER 2 YEARS FOLLOW-UP IN A COHORT OF EUROPEAN UNTREATED HEPATITIS B (HBV) INFECTED PATIENTS: A PROSPECTIVE LONGITUDINAL STUDY (ALBATROS STUDY) (2014) (0)
Sex Specific Differences in Nosocomial Infections in Patients with Decompensated Liver Cirrhosis (2021) (0)
[552] IV DRUG ABUSE IS MORE IMPORTANT FOR LIVER INJURY THAN HEPATITIS C VIREMIA IN YOUNG ANTI-HCV POSITIVE PATIENTS (2007) (0)
355 ENHANCED INTERFERON ALPHA-DEPENDENT TRAIL EXPRESSION BUT COMPRISED CYTOKINE PRODUCTION OF NK CELLS IN CHRONIC HEPATITIS C IN RELATION TO THE IL28B GENOTYPE (2013) (0)
Significant compartment-specific impact of the RNA extraction and quantification method on the sensitivity of hepatitis E virus detection: implications for clinical care? (2020) (0)
Inadvertent “off label” DAA treatment in the real-world and importance for virologic outcome - data from the German hepatitis C-Registry (DHC-R) (2020) (0)
[661] ROLE OF THE CD26/ADA/ADENOSINE SYSTEM IN VIRAL AND AUTOIMMUNE CHRONIC LIVER DISEASES (2007) (0)
Clinical impact, morbidity and mortality of Hepatitis E at tertiary referral centres in central Europe (2018) (0)
Effect of immunosuppressive drugs on regulatory T cells after liver transplantation (2013) (0)
Real World Experience of Prescribing Tenofovir Alafenamide for Chronic Hepatitis B Patients in Germany (2019) (0)
Screening for HCV-specific T cell responses: THE USE OF PEPTIDE POOLS IMPAIR THE PROLIFERATION OF ANTIGEN SPECIFIC CD8 T-CELLS (2008) (0)
TIPS insertion leads to partial reversal of systemic inflammation in patients with decompensated liver cirrhosis (2022) (0)
Viral and ALT kinetics after nucleos (t)ide analogue withdrawal among patients who remain off-therapy: results from a global, multi-ethnic cohort of chronic hepatitis B patients (RETRACT-B study) (2022) (0)
P178: Quantitative HBsAg level and its potential applications in patients with hepatitis D coinfection (2015) (0)
Akute Hepatitis-C-Infektion (2004) (0)
MELD-score underestimates mortality in patients with nosocomial spontaneous bacterial peritonitis (2018) (0)
Endothelial dysfunction determines severe COVID-19 in combination with dysregulated lymphocyte responses and cytokine networks (2021) (0)
Proton pump inhibitors are associated with a higher risk for spontaneous bacterial peritonitis in patients with liver cirrhosis and ascites (2017) (0)
Soluble inflammatory molecules do not completely normalize despite early treatment of acute symptomatic hepatitis C (2020) (0)
High real-world effectiveness of elbasvir/grazoprevir (EBR/GZR) in a HCV genotype 1 (GT1) population with a migration background and predominant subtype 1b infection: results from the German Hepatitis C Registry (DHC-R) (2019) (0)
355 APPLYING HEPATITIS B GUIDELINES IN EUROPE: HOW EXPENSIVE IS A STATE-OF-THE ART MANAGEMENT OF HBV INFECTION? (2011) (0)
14 Cross-genotype-reactivity of the immunodominant HCV-CD8 T-cell epitope NS3-1073: Significance for the development of peptide-based vaccines against HCV (2006) (0)
435 ANTI-HDV-IgM AS A MARKER OF DISEASE ACTIVITY IN HEPATITIS DELTA (2013) (0)
Long-term kinetics of quantitative HBsAg levels during successful oral antiviral therapy of chronic hepatitis B (2007) (0)
627 IN VITRO PROLIFERATION OF ANTIGEN-SPECIFIC CD8+ T CELLS CAN BE INHIBITED BY USING PEPTIDE POOLS (2008) (0)
Application of CT contrast medium is not associated with an increased risk for acute kidney injury in patients with decompensated cirrhosis (2022) (0)
Biomarkers to predict the clinical outcome of hepatitis delta (2015) (0)
Comprehensive analysis of NK cell phenotype and function during the initial phase of antiviral therapy: distinct roles of Ribavirin and Interferon alpha (2013) (0)
SAT-204-Hepatitis E virus antigen in urine as a useful diagnostic Background and aims: for monitoring infection and detection of recent infection (2019) (0)
Differential escape pathways from the dominant CD8 T cell epitope in HBV core18 – 27 depend on the HLA class I genotype (2018) (0)
HBsAg decline after interrupting nucleos(t)ide analogue therapy in HVeAg-negative chronic hepatitis B (2015) (0)
Variables associated with persistence of elevated ALT after SVR in patients with chronic hepatitis C: Data from the German Hepatitis C-Registry (DHC-R) (2018) (0)
799 EFFECTS OF RIBAVIRIN ON NK CELL PHENOTYPE AND FUNCTION IN HEPATITIS C VIRUS INFECTION (2012) (0)
[All-oral, interferon-free therapies for patients with chronic genotype 1 hepatitis C virus infection]. (2014) (0)
193 PROGNOSTIC SERUM BIOMARKERS FOR GRAFT SURVIVAL AFTER LIVER TRANSPLANTATION IN HEPATITIS C PATIENTS (2012) (0)
Identification of a highly cross-reactive CD8+ T cell repertoire that recognizes a hepatitis E virus peptide and an apoptotic epitope (2017) (0)
Management of hepatitis B virus infection: Impact of migrational background, education and household income (2010) (0)
[Chronic hepatitis B and D (delta) : Current and future treatments]. (2018) (0)
621 LACK OF CORRELATION BETWEEN PD-1 EXPRESSION ON T CELLS AND CLINICAL PARAMETERS FROM PATIENTS WITH CHRONIC HEPATITIS C (2008) (0)
Cross-Reactive T Cell Response Exists in Chronic Lymphocytic Choriomeningitis Virus Infection upon Pichinde Virus Challenge (2022) (0)
Co-morbidities and risk for drug-drug-interactions in HCV GT 1 patients treated with elbasvir/grazoprevir from the German Hepatitis C Registry (DHC-R) (2018) (0)
1058 Real World Effectiveness and Safety of Glecaprevir/Pibrentasvir in Adults With Chronic Hepatitis C Virus Infection: A Meta-Analysis (2019) (0)
The role of HbA1c as a risk factor for the development of spontaneous bacterial peritonitis in patients with decompensated liver cirrhosis (2018) (0)
Characterization of immune cells in patients with liver cirrhosis with and without spontaneous bacterial peritonitis (2019) (0)
Kinetic of Hepatitis B core-related antigen (HBcrAg) levels in chronic hepatitis B during NUC therapy (2015) (0)
Serum cholinesterase is an independent predictor of hepatic encephalopathy, acute-on-chronic liver failure and mortality after transjugular intrahepatic portosystemic shunt insertion in patients with liver cirrhosis (2020) (0)
Characterization of in-vitro responses to immune modulation of HBV core 18 -specific vs HBV pol455-specific CD8+ T cells (2021) (0)
Response to Taiwan is on track of accelerating hepatitis C elimination by 2025 (2020) (0)
Predictors of nosocomial spontaneous bacterial peritonitis in patients with decompensated liver cirrhosis and ascites (2017) (0)
Inhibition of antigen-specific CD8+ T cell proliferation using peptide pools- Possible mechanisms (2009) (0)
P060: Incidence of hepatocellular carcinoma in chronic hepatitis B patients responders to nucleoside analogue treatment (2015) (0)
P179: Plasma cytokine and chemokine patterns during PEG‐IFNa‐2a therapy of chronic hepatitis delta (2015) (0)
Hepatitis E virus-specific T cell responses against non-structural viral proteins in patients with ongoing and resolved hepatitis E (2017) (0)
433 QUANTIFICATION OF LARGE, MIDDLE AND SMALL HEPATITIS B VIRUS (HBV) SURFACE PROTEIN (HBsAg) FRACTIONS IN PATIENTS WITH ACUTE HEPATITIS B (2013) (0)
P061: Interruption of nucleos(t)ide analogue therapy in HBeAg‐negative chronic hepatitis B ‐ a new concept to achieve HBsAg reduction? (2015) (0)
P069: Risk factors associated with type 2 diabetes mellitus in patients with chronic hepatitis B: a cross‐sectional study with pair‐matched controls (2015) (0)
[465] TRAIL-EXPRESSION ON NK CELL SUBSETS IN RESPONSE TO TYPE-I-INTERFERONS IN VIRAL HEPATITIS (2007) (0)
High real-world efficacy of elbasvir/grazoprevir (EBR/GZR) in genotype 1 (GT1) infected patients with and without liver cirrhosis: results from the German Hepatitis C Registry (DHC-R) (2019) (0)
Utilization of elbasvir/grazoprevir (EBR/GZR) and adoption of resistance associated substitutions (RAS) testing in real-world treatment of HCV genotype 1 (GT1) infection: results from the German Hepatitis C Registry (DHC-R) (2018) (0)
Title Page / Editorial Board / Contents / Imprint (2016) (0)
Application of CT-contrast media is not associated with a higher risk for acute kidney injury in patients with decompensated liver cirrhosis (2022) (0)
O‐27: Early HCV RNA kinetics predict relapse to sofosbuvir/ribavirin dual therapy (2015) (0)
Disease progression is affected by pattern of serum alanine aminotransferase dynamics in a cohort of patients with hepatitis B e antigen-negative chronic infection: 4 years follow-up of a prospective longitudinal study (ALBATROS study) (2018) (0)
Association between low anti-HBc level and lower risk of virological relapse after nucleos(t)ide analogue cessation in HBe antigen negative chronic hepatitis B patients (2022) (0)
Low HBcrAg and HBsAg levels identify patients most likely to achieve sustained response after nucleos(t)ide analogue cessation: results from a global individual patient data meta-analysis (create study) (2020) (0)
P722 PERFORMANCE AND VALUE OF IFN-LAMBDA3 AND IFN-LAMBDA4 GENOTYPING IN PATIENTS WITH CHRONIC HEPATITIS C (CHC) GENOTYPE 2/3 IN A REAL WORLD SETTING (2014) (0)
Higher rates of virological relapse after nucleos (t)ide analogue withdrawal in HBeAg-negative versus positive chronic hepatitis B patients: results from a global, multi-ethnic cohort of patients with chronic hepatitis B (RETRACT-B Study) (2022) (0)
284 COMPREHENSIVE PHENOTYPING OF IMMUNE CELLS IN CHRONIC HEPATITIS DELTA (2011) (0)
Relevance of quantitative HBsAg (qHBsAg) during long-term treatment of chronic hepatitis B with nucleos(t)ide analogues (NUCs) (2011) (0)
Unexpected increase of Hepatitis B Surface Antigen (HBsAg) levels during treatment with nucleos(t)ide analogous 12–24 months before virological breakthrough and resistance (2012) (0)
Serum cholinesterase, an underestimated marker in the prediction of acute-on-chronic liver failure, organ failure and LTx-free survival in patients with liver cirrhosis? (2020) (0)
Frequency and functional analysis of variants of the immunodominant epitope NS3–1073: Relevance for vaccine design (2006) (0)
292 ASSOCIATION OF HBSAG DECLINE WITH INNATE AND ADAPTIVE IMMUNE RESPONSES DURING ACUTE HEPATITIS B VIRUS INFECTION (2011) (0)
548 UNEXPECTED INCREASE OF HEPATITIS B SURFACE ANTIGEN (HBSAG) CONCENTRATIONS DURING TREATMENT WITH NUCLEOS(T)IDE ANALOGUES 12-24 MONTHS BEFORE VIROLOGICAL BREAKTHROUGH AND RESISTANCE (2012) (0)
Specific alterations in muc2 expression in the chronically inflammed colon of IL10 deficient mice (2000) (0)
State-of-the-Art Lecture: Treatment of hepatitis C (2009) (0)
Imprints of post-liver transplantation: HCV recurrence on immune cell compartment persist despite achieving therapy-induced SVR (2020) (0)
Improved pharmacodynamics and pharmacokinetics after i.v. application of peginterferon alfa‐2a in hepatitis C null responders (2015) (0)
Serum cytokines and HBsAg decline in patients with acute Hepatitis B Virus (HBV) infection (2013) (0)
Quantification of Large, Middle and Small Hepatitis B virus (HBV) surface protein (HBsAg) fractions in patients with Hepatitis Delta (2014) (0)
P0667 : Interruption of nucleos(t)ide analogue therapy for HBeAg-negative chronic hepatitis B – A new concept to achieve HBsAg decline? (2015) (0)
P070: Cytokine patterns of patients with HCV/HBV co‐infection (2015) (0)
Bulevirtide 2 mg/day monotherapy in patients with chronic hepatitis delta with or without cirrhosis: a multicenter european cohort real-life study (2022) (0)
[284] ADENOSINE AND INTERFERON ALPHA SYNERGISTICALLY INCREASE INTERFERON GAMMA PRODUCTION OF PBMC VIA THE A3-RECEPTOR (2007) (0)
Table of contents (2017) (0)
Current and Future Treatment of Chronic Hepatitis C Genotype 2 and 3 (2013) (0)
Sofosbuvir plus velpatisvir for 8 weeks in patients with acute hepatitis C: multicenter, single arm, phase 2 study (The HepNet acute HCV-V study) (2022) (0)
896 INHIBITORY MECHANISM OF PEPTIDE POOLS ON THE PROLIFERATION OF ANTIGEN-SPECIFIC CD8+ T CELLS (2009) (0)
445 Function and phenotype of peptide-vaccine induced HCV specific CD8+ T cells vs. acute and chronic hepatitis C (2006) (0)
Limited value of HBV-RNA levels for the prediction of relapse after discontinuation of nucleos (t)ide analogue therapy in HBe antigen negative chronic hepatitis B patients (2022) (0)
Rapid and Sustained Improvements of Liver Stiffness Values in HCV-Infected Patients Treated with Direct Antiviral Drugs (2016) (0)
819 IMPROVED PHARMACODYNAMICS AND PHARMACOKINETICS AFTER INTRAVENOUS APPLICATION OF PEG-INTERFERON alfa-2a 180 μg IN CHRONIC HEPATITIS C GENOTYPE 1 NULLRESPONDERS TO PEGINTERFERON/RIBAVIRIN. THE IVAN STUDY (2013) (0)
84 ADAPTIVE HEV-SPECIFIC T-CELL RESPONSES ARE ASSOCIATED WITH CONTROL OF HEV INFECTION (2011) (0)
IFN-alpha induced IFN-gamma production of NK cells is not inhibited but enhanced by adenosine (2009) (0)
Eligibility and safety of sofosbuvir in a real-world single center cohort of patients with advanced cirrhosis, including decompensated cirrhosis (2015) (0)
Early on treatment detection of nucelos(t)ide analogue resistant minor variants of Hepatitis B virus (HBV) with ultra deep-pyrosequencing (UDPS) in chronic hepatitis B(CHB) patients (2013) (0)
Comprehensive phenotyping of natural killer cells in acute and chronic viral hepatitis (2013) (0)
Successful triple therapy of patients with chronic hepatitis C genotype 1 infection leads to significant improvement of non-invasive liver fibrosis tests (2014) (0)
Clinical and molecular characterization of the human kidney as extrahepatic site of hepatitis E virus infection (2020) (0)
Reply to Liaw. (2018) (0)
86 INDIVIDUAL HIERARCHIES OF CO-STIMULATORY RECEPTORS ON HCV-SPECIFIC CD8+ T-CELLS IN CHRONIC HEPATITIS C (2010) (0)
Meetings and Conferences (2016) (0)
539 TGFB EXPRESSION IN CD4+/CD25+/FOXP3+/CD127LOW CELLS MAY HELP TO DISTINGUISH HCV HEPATITIS FROM REJECTION IN LIVER TRANSPLANT RECIPIENTS (2011) (0)
P140: Drug‐drug interactions with novel all oral interferon free antiviral agents ‐ all issues solved? (2015) (0)
Safety of add on Interferon-alpha-2a in hepatitis B patients receiving effective nucleos(t)de therapy: Interim results from the German multicenter PADD-ON trial (2014) (0)
Impact of Dynamic Viral and Biochemical Parameters on Progression of Liver Fibrosis in a Cohort of Inactive European Hepatitis B (HBV) Carriers: A Prospective Longitudinal Study (Albatros Study) (2016) (0)
Peritoneal cytokines of patients with decompensated liver cirrhosis drive NK and T cells towards an activated phenotype (2021) (0)
Pancreatic tumor and Gitelman syndrome (2011) (0)
Does Antiviral Treatment Affect the Clinical Long-Term Outcome of Hepatitis Delta? (2016) (0)
Incidence of hepatic decompensation after nucleos(t)ide analogue withdrawal: Results from a large, international, multi-ethnic cohort of patients with chronic hepatitis B (RETRACT-B study). (2023) (0)
HLA-B*27-restricted CD8+ T cell response against hepatitis B virus: viral escape as central mechanism of T cell failure (2021) (0)
P104: Serum biomarker profile can predict the outcome of acute HCV infection (2015) (0)
Sofosbuvir plus velpatasvir for 8 weeks in patients with acute hepatitis C: The HepNet acute HCV-V study (2022) (0)
Eight-weeks of glecaprevir/pibrentasvir is well tolerated and yields high sustained virological response in HCV-infected treatment-naive patients with compensated cirrhosis: the CREST study (2022) (0)
397 LONGITUDINAL ANALYSIS OF QUANTITATIVE SERUM HBSAG IN HBV/HIV COINFECTED PATIENTS (2011) (0)
PS-030-Cure of hepatitis C virus has limited impact on the functional and mitochondrial impairment of HCV-specific CD8+ T-cell responses (2019) (0)
The association of 2B4 up-regulation and SAP down-regulation indicates exhaustion of virus-specific CD8+ T cells (2011) (0)
Real-world efficacy of EBR/GZR in HCV GT1 patients with multiple comorbidities and medications: results from the DHC-R (2020) (0)
Does response to antiviral therapy affect the clinical long-term outcome of hepatitis delta? (2016) (0)
Real-World Safety, Effectiveness, and Patient-Reported Outcomes in Patients with Chronic Hepatitis C Virus Infection Treated with Glecaprevir/Pibrentasvir: Updated Data from the German Hepatitis C-Registry (DHC-R) (2022) (0)
Health-related quality of life (HRQOL) before and after treatment of genotype 1 (GT1) infection with elbasvir/grazoprevir (EBR/ GZR): results from the German hepatitis C registry (DHC-R) (2020) (0)
IL-12 rather than immune checkpoint inhibitors contribute to the functional restoration of hepatitis D virus-specific T-cells (2015) (0)
Hepatitis A virus superinfection suppresses hepatitis C virus replication and may lead to spontaneous HCV clearance (2002) (0)
complicationsviral hepatitis C: efficacy, side effects, and (2007) (0)
P689 DIFFERENTIATION OF PATIENTS WITH HBeAg NEGATIVE HEPATITIS VERSUS HBeAg NEGATIVE INACTIVE CARRIER STATUS BY SERUM CYTOKINES AND CHEMOKINES (2014) (0)
Machine learning identifies immune profile to predict virological relapse after stopping nucleos(t)ide analogue therapy in HBeAg negative chronic hepatitis B (2020) (0)
Post-treatment elevated gamma-glutamyl transferase is the best predictor for future outcomes in HCV patients achieving sustained virological response-data from the german hepatitis C-registry (DHC-R) (2022) (0)
Corrigendum: Increasing Number of Individuals Receiving Hepatitis B nucleos(t)ide Analogs Therapy in Germany, 2008–2019 (2022) (0)
Characterization of T cell responses after stopping HBV therapy with nucleos(t)ide analogues (NA) in HBeAg-negative patients (2016) (0)
Editorial: Das Kompetenznetz Hepatitis (2007) (0)
P103: Effect of endogenous ligands of the high densitiy lipoprotein‐receptor scavenger receptor class B type I on the replication cycle of the hepatitis C virus (2015) (0)
Real-world efficacy of elbasvir/grazoprevir in HCV GT1 infected diabetics: results from the German Hepatitis C Registry (2020) (0)
Response to discontinuation of nucleos(t)ide analogue treatment in HBeAg-negative chronic hepatitis B: results from the Stop-NUC trial (2020) (0)
THU-125-High real-world effectiveness of elbasvir/grazoprevir in PWID on opioid substitution therapy with HCV genotype 1 infection: Results from the German hepatitis C registry (DHC-R) (2019) (0)
Thanks to Reviewers (2016) (0)
FRI-208-Predictors of treatment response during addition of pegylated Interferon alfa-2a to an onging nucleos (t)id treatment in chronic hepatitis B: Results from the PADD-ON trial (2019) (0)
Co-infection alters CD8 T cell immunity and immunoprotection (105.27) (2012) (0)
Effect of Helicobacter pylori on leptin and leptin receptor expression in human gastric epithelial cells (2000) (0)
THU-143-High effectiveness of elbasvir/grazoprevir treatment in patients with HCV genotype 1a infection in German real-world: Results from the German hepatitis C registry (DHC-R) (2019) (0)
HLA-A2 restricted CD8+ T cell immune hierarchy towards full length hepatitis E virus for T cell-based therapy in chronic HEV (2018) (0)
Transjugular intrahepatic portosystemic shunt in cirrhotic elderly patients with refractory ascites - to do or not to do? (2020) (0)
Real-world effectiveness and safety of glecaprevir/ pibrentasvir for the treatment of patients with chronic HCV infection: A meta-analysis Graphical (2020) (0)
Delayed decrease of splenic stiffness in chronic hepatitis C virus patients receiving direct-acting antivirals (2017) (0)
Chronic hepatitis C virus infection irreversibly impacts human natural killer cell repertoire diversity (2018) (0)
Dynamics of natural killer cell responses to hepatitis delta virus infection during the course of interferon alpha treatment (P6070) (2013) (0)
P0610 : Dynamic prediction of inactive chronic hepatitis B using repeated HBsAg and HBV DNA level measurements through long-term follow-up (2015) (0)
Patients with chronic HCV and decompensated cirrhosis are at risk for MELD purgatory (2022) (0)
Management of Patients with Acute Hepatitis C (2021) (0)
Role of the CD26/ADA/adenosine system in viral and autoimmune chronic liver disease (2007) (0)
COMPREHENSIVE IMMUNOPHENOTYPING OF TREGS AND SERUM CYTOKINES MAY HELP TO DISTINGUISH HCV HEPATITIS FROM REJECTION IN LIVER TRANSPLANT PATIENTS (2012) (0)
[Which treatment options are validated for chronic viral hepatitis?]. (2013) (0)
Low rate of drug-drug interaction management during interferon-free simeprevir therapy – an integrated analysis of interventional and observational clinical studies (2017) (0)
Utilization and effectiveness of elbasvir/grazoprevir and adoption of resistance-associated substitutions testing in real-world treatment of hepatitis C virus genotype 1A infection: results from the German Hepatitis C-Registry (2020) (0)
IL-28B Genotype is not associated with early HCV-RNA negativity in patients with symptomatic acute HCV infection (2013) (0)
393 Impaired trail-dependent cytotoxicity of CD1C-positive dendritic cells in chronic hepatitis C virus infection (2004) (0)
Immune Responses in Acute and Chronic Hepatitis C (2007) (0)
P122: Type I interferon elevates co‐regulatory receptor expression on CMV‐ and EBV‐specific CD8 T cells in Chronic Hepatitis C (2015) (0)
Large scale biomarker profiling reveals distinct cytokine and chemokine signatures distinguishing different acute and chronic hepatitis virus infections (2015) (0)
P0565 : Cytokine patterns of patients with HCV/HBV co-infection (2015) (0)
Role of BMI, age and sex for disease severity in acute hepatitis C: Analysis of 254 patients from the German Hep-Net acute HCV cohort (2008) (0)
Predictors of HBsAg loss after cessation of nucleo (s)tide analogue therapy in asian patients with low HBsAg levels (2022) (0)
Long-term outcome of hepatitis delta compared to HBV monoinfection (2018) (0)
Factors predicting clinical endpoints in Hepatitis Delta: A retrospective-prospective single center study (2013) (0)
EBV and Murine Vaccinia Virus Infections Mediate Heterologous Immunity in Human CD8 T Cell Cross-Reactivity Networks (2010) (0)
P185: Cellular immune responses in persistent hepatitis delta virus infection (2015) (0)
The role of HDV in the natural history of the persistent HBV infection (2011) (0)
Comprehensive characterization of Mucosal-Associated invariant T (MAIT) cells in patients with hepatitis E virus infection (2022) (0)
317 DISTINCT T CELL RESPONSES AND CYTOKINE PATTERN IN HEPATITIS DELTA (2010) (0)
Clinical Utility of Hepatitis B Core-Related Antigen (HBcrAg) in the Treatment of Hepatitis Delta (2016) (0)
Heterologous Immunity Dependent on TNF under Conditions of Resistance to Vaccinia Virus Is Less (2009) (0)
Unexplained jaundice after squirrel bite. It's not what you look at that matters, it's what you see (H. D. Thoreanu). (2011) (0)
Blood and ascites pharmacokinetics of meropenem in patients with nosocomial spontaneous bacterial peritonitis and decompensated liver cirrhosis (2020) (0)
299 EXPRESSION OF THE 2B4 ADAPTOR MOLECULE SAP AS A DETERMINANT FOR CD8+ T CELL FUNCTION AND DYSFUNCTION IN VIRAL HEPATITIS (2011) (0)
287 COMPREHENSIVE PHENOTYPING OF REGULATORY T CELLS FROM PATIENTS AFTER LIVER TRANSPLANTATION REVEALS DISTINCT T-REG PROPERTIES ASSOCIATED WITH GRAFT HEPATITIS AND REJECTION (2011) (0)
P153 NK-CELL FREQUENCY AND PHENOTYPE AFFECT THE OUTCOME OF ACUTE HEPATITIS VIRUS C INFECTION (2014) (0)
IDDF2019-ABS-0212 Real-world effectiveness and safety of glecaprevir/pibrentasvir in adults with chronic hepatitis C virus infection: a meta-analysis (2019) (0)
Reverse Inflammaging: Biological age is accelerated in chronic HCV patients and decelerates after HCV cure (2022) (0)
P139: Development of treatment model for HIV/HCV co‐infected OST patients as the basis for scaling up access to HCV treatment for key populations in Ukraine (2015) (0)
Serum biomarker profile can predict the outcome of acute HCV infection (2015) (0)
P042: Hepatitis B surface proteins (SHBs, LHBs and MHBs) decline after stopping of nucleos(t)ide analogue therapy in HBeAg‐negative patients (2015) (0)
Rapid and sustained improvements of liver stiffness values in HCV-infected patients treated with direct-acting antiviral drugs (2016) (0)
P6: Prevalence of HCV, HBV and HIV infections among hemophiliac (2014) (0)
Preexisting Hepatitis C Virus (HCV)-Specific CD8+ T Cells are Abundant in HCV-Seronegative Individuals and can Show Cross-Reactivity to Common Pathogens (2016) (0)
677 FREQUENCY AND T-CELL RECEPTOR (TCR) REPERTOIRE OF HEPATITIS C VIRUS (HCV)-SPECIFIC CD8 T-CELLS IN HCV-SERONEGATIVE INDIVIDUALS (2010) (0)
Hepatitis C virus (HCV)-specific CD8 T-cells in HCV-seronegative individuals: Frequency and T-cell receptor repertoire (TCR) (2011) (0)
856 CLINICAL SIGNIFICANCE OF DRUG–DRUG-INTERACTIONS IN THE ERA OF DIRECT ACTING ANTIVIRAL AGENTS AGAINST HEPATITIS C – A REAL-WORLD EXPERIENCE (2013) (0)
Spontaneous clearance of hepatitis C viremia in the absence of humoral immunity and very low levels of cellular HCV-specific immunity (2006) (0)
Broad and cross-genotype-specific T cell responses during acute hepatitis E virus infection (2015) (0)
P0581 : Prediction of HBsAg seroclearance and HBsAg seroconversion in a cohort of inactive european hepatitis B (HBV) carriers: A prospective longitudinal study (albatros study) (2015) (0)
Leitlinienreport zur aktualisierten S3-Leitlinie der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) zur Prophylaxe, Diagnostik und Therapie der Hepatitis-B-Virusinfektion (2021) (0)
Transjugulärer intrahepatischer portosystemischer Shunt bei Patienten höheren Alters mit Leberzirrhose und therapierefraktärem Aszites - Wagen oder lieber bleiben lassen? (2020) (0)
Untersuchung des Langzeitverlaufs von Patienten mit einer niedrig-replikativen chronischen Hepatitis B-Infektion, die keine antivirale Therapie erhalten: 2 Jahres-Daten einer deutschen prospektiven Studie (ALBATROS Studie) (2015) (0)
Hinzunahme von pegyliertem-Interferon-alpha zu einer bestehenden Nukleos(t)id-Analoga Therapie der HBeAg negativen Hepatitis B: Ergebnisse der prospektiven PADD-ON Studie (2018) (0)
Strategietreffen: Virushepatitis in Deutschland eliminieren – Was ist zu tun? (2023) (0)
Wirksamkeit und Sicherheit einer Sofosbuvir-Monotherapie bei Patienten mit chronischer Hepatitis E-Die HepNet SofE Studie (2019) (0)
Pharmakokinetik von Meropenem in Aszites und Plasma bei PatientInnen mit nosokomialer spontan bakterieller Peritonitis und Leberzirrhose (2020) (0)
Entwicklung des Krankheitsbildes und der Behandlung von Patienten mit chronischer Hepatitis C-Infektion (HCV) unter Real-World Bedingungen in Deutschland: Erfahrungen aus 14 Jahren mit mehr als 16.000 Patienten (2017) (0)
Chronische Hepatitis B und D (delta) (2018) (0)
Chronische Hepatitis C - Management von Patienten, bei denen die antivirale Therapie versagt hat (2005) (0)
Häufigkeit, Schwere und Konsequenz von PEG-IFNa-assoziierten Flares bei einer HDV-Infektion (2019) (0)
Bedeutung der heterologen Immunität und CD8 T-Zell Kreuzreaktivität für den klinischen Verlauf und die Leberpathologie im Rahmen einer LCMV-Infektion (2006) (0)
Zoonotisch übertragene Hepatitis E Virus als Ursache akuter und chronischer Hepatitiden bei Lebertransplantierten in Deutschland (2009) (0)
Versehentliche “Off-label” DAA-Behandlung und virologisches Ansprechen - Daten aus dem Deutschen Hepatitis C-Register (DHC-R) (2020) (0)
Real-Life-Daten zur Sicherheit, Wirksamkeit und Lebensqualität bei HCV-Patienten, die mit Glecaprevir/Pibrentasvir behandelt wurden: Daten aus dem Deutschen Hepatitis C-Register (2019) (0)
Erfahrungen in der Therapie der Hepatitis E Virusinfektion mit Ribavirin (2012) (0)
Kenntnisse und Versorgung von Hepatitis-B-Infizierten in Deutschland (2012) (0)
Begrenztes Wissen über Hepatitis B und schlechte Durchimpfung von Verwandten von Hepatitis B Patienten in Deutschland (2009) (0)
Bedeutung nosokomialer Infektionen und eines akut-auf-chronischen Leberversagens für die Behandlungskosten bei dekompensierter Leberzirrhose (2019) (0)
Reaching the unreachable: Strategien für die effektive HCV Behandlung bei Patienten mit fortgesetztem intravenösen Drogengebrauch - eine Real-World Erfahrung (2021) (0)
Prognostische Biomarker für den Langzeitverlauf von Hepatitis Delta (2015) (0)
Verbesserte Pharmakodynamik und Pharmakokinetik nach intravenöser Applikation von Peg-Interferon alfa-2a bei Patienten mit Hepatitis C Genotyp 1 und Null Response auf eine Therapie mit Peg-Interferon alfa/Ribavirin (IVAN-Studie) (2013) (0)
Was ist gesichert in der Therapie der chronischen Virushepatitis? (2013) (0)
Therapie der Hepatitis C in Deutschland. Ergebnisse aus dem Deutschen Hepatitis C-Register 4 Jahre nach Zulassung der neuen direkt-antiviralen Substanzen (DAAs) (2018) (0)
Therapie der Hepatitis C in Deutschland nach Zulassung der neuen direkt-antiviralen Substanzen: Erste Ergebnisse aus dem Deutschen Hepatitis C-Register (2015) (0)
Der Einfluss des Alanin-Aminotransferase (ALT)-Verlaufs auf die Krankheitsprogression bei Patienten mit chronischer Hepatitis B e Antigen (HBeAg)-negativer Infektion: 4 Jahres-Daten einer prospektiven longitudinalen Studie (ALBATROS Studie) (2019) (0)
Eingeschränkte TRAIL-abhängige Zytotoxizität myeloider dendritischer Zellen bei der chronischen Hepatitis C (2015) (0)
Niedrige SVR-Raten bei der Therapie der chronischen Hepatitis C-Virusinfektion vom Genotyp 2 mit Sofosbuvir und Ribavirin unter Real-World-Bedingungen: Deutsches Hepatitis C-Register (DHC-R) (2016) (0)
Hepatitis C: Eine Pille für alle HCV-Genotypen? (2016) (0)
Einfluss von Diabetes mellitus (Typ 2) auf Inzidenz und Verlauf einer spontan bakteriellen Peritonitis bei Patienten mit Leberirrhose und Aszites (2018) (0)
Fehlende Korrelation zwischen PD-1 Expression auf T-Zellen und klinischen Parametern in Patienten mit chronischer Hepatitis C Infektion (2008) (0)
Prädiktion der Fibroseprogression bei Patienten mit niedrig-replikativer chronischer Hepatitis B (HBV) – Infektion: 3 Jahres-Daten einer prospektiven longitudinalen Studie (ALBATROS Studie) (2016) (0)
Assoziation zwischen niedrigen Anti-HBc Level und niedriegerem Risiko eines virologischen Relapse nach Absetzen von Nukleos(t)id Analoga in HBe Antigen negativen Patienten (2021) (0)
Geschlechtsspezifische Unterschiede bei Inzidenz und Verlauf nosokomialer Infektionen bei PatientInnen mit dekompensierter Leberzirrhose (2019) (0)
Sicherheit und Wirksamkeit von direkt antiviralen Substanzen für die Therapie der chronischen Hepatitis- C -Virusinfektion vom Genotyp 4: Daten aus dem Deutschen Hepatitis C-Register (DHC-R) (2016) (0)
Reply: (2006) (0)
Lebererkrankungen – frühzeitig diagnostizieren und handeln (2009) (0)
Chronische Virushepatitis - Update 2008 (Stand März 2008) (2008) (0)
Die wichtigsten Änderungen der S3-Leitlinie der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) zur Prophylaxe, Diagnostik und Therapie der Hepatitis-B-Virusinfektion im Überblick (2021) (0)
Erstbeschreibung der T-Zellantwort gegen das gesamte Genom des Hepatitis E Virus (2016) (0)
Klinische Bedeutung der HBs Antigen-Konzentration bei Patienten mit chronischer HBV/HCV-Koinfektion (2009) (0)
Verlauf einer chronischen HCV-Infektion im Verlauf einer akuten Delta Hepatitis (2007) (0)
24 Wochen Therapie mit Pegyliertem Interferon Alfa-2B bei Patienten mit akuter Hepatitis C Infektion (2004) (0)
Therapie von COVID-19 unter Berücksichtigung von Lebererkrankungen (2023) (0)
Infektionskrankheiten der Leber (2011) (0)
Dosisabhängige Effekte von Protonenpumpeninhibitoren auf den Verlauf einer spontan bakteriellen Peritonitis bei Patienten mit Leberzirrhose und Aszites (2017) (0)
Prävalenz und klinische Bedeutung von Hepatitis C Virus (HCV) Genotyp 2k/1b Chimären (2016) (0)
Hepatitis A, B, C, D, E: Trotz gleicher Namen viele Unterschiede (2015) (0)
Getunnelte Peritonealkatheter als alternative Versorgungsmöglichkeit von therapierefraktärem Aszites bei Patienten mit Leberzirrhose (2021) (0)
Die Baseline HCV RNA Viruslast als Entscheidungshilfe für die Behandlungsdauer mit Ledipasvir/Sofosbuvir bei HCV Genotyp-1-Patienten: Ergebnisse aus dem Deutschen Hepatitis C-Register (DHC-R) (2017) (0)
II. Therapie der Hepatitis B und hepatobiliäre Onkologie (2010) (0)
Caspasen-Aktivität im Serum als prädiktiver Marker für das Therapieansprechen bei chronischer Hepatitis C Virus Infektion (2006) (0)
Paradigmenwechsel in der Therapie viraler Hepatitiden (2012) (0)
Sicherheit und Wirksamkeit einer 8-Wochen-Therapie mit Glecaprevir/Pibrentasvir bei therapienaiven Patienten mit kompensierter Zirrhose: Daten aus dem Deutschen Hepatitis C-Register (2020) (0)
Drogenkonsum ist bedeutsamer für die Leberschädigung bei jungen anti-HCV positiven Patienten als die HCV Virämie (2006) (0)
Maßgeschneiderte Therapie der Virushepatitis der Gegenwart und Zukunft (2017) (0)
Prädiktion von HBsAg Verlust und HBsAg Serokonversion bei Patienten mit niedrig-replikativer chronischer Hepatitis B (HBV) – Infektion: 2 Jahres-Daten einer deutschen prospektiven longitudinalen Studie (ALBATROS Studie) (2015) (0)
Phänotypische Charakterisierung von HCV-spezifischen CD8+ T-Zellen nach HCV-Peptidimpfung vs. akute und chronische Hepatitis C (2006) (0)
Sicherheit und Wirksamkeit interferonfreier antiviraler Therapien in der Behandlung fortgeschrittener HCV-assoziierter Leberzirrhose: Ergebnisse aus dem Deutschen Hepatitis C-Register (DHC-R) (2016) (0)
Thrombozytenzahl, Albumin und Bilirubin identifizieren Patienten mit chronischer Hepatitis C Zirrhose mit hohem Risiko für ein Therapieversagen und schwerwiegende Nebenwirkungen während einer Triple-Therapie mit Boceprevir oder Telaprevir (2014) (0)
Einfluss einer spontan bakteriellen Peritonitis, nosokomialer Infektionen und eines akut auf chronischen Leberversagens auf die Behandlungserlöse bei Patienten mit dekompensierter Leberzirrhose in Deutschland (2020) (0)
Behandlung der chronischen Hepatitis-C-Virusinfektion vom Genotyp 3 mit direkt antiviralen Substanzen: Daten aus dem Deutschen Hepatitis C-Register (DHC-R) (2016) (0)
KAPITEL B8 – Leber (2008) (0)
Schritt für Schritt zur perfekten Hepatitis-C-Therapie für alle Genotypen (2015) (0)
Bedeutung der Histologie für die Diagnose und Prognose chronischer Lebererkrankungen aus internistischer Sicht (2006) (0)
Langzeitnachbeobachtung nach IFN-freier Therapie bei fortgeschrittener HCV-assoziierter Leberzirrhose: Kontinuierliche Verbesserung der Leberfunktionsparameter – Ergebnisse aus dem Deutschen Hepatitis C-Register (DHC-R) (2017) (0)
Seroprävalenz von Antikörpern/Antigen gegen Hepatitisviren A, B, C, D und E bei Flüchtlingen in Deutschland im Jahr 2015 (2016) (0)
Sequentielle Therapie mit Interferon alfa und Lamivudin als Konzept für die Therapie der chronischen Hepatitis B: Höhere Chance der HBs-Serokonversion? (2006) (0)
Genotypen-spezifische Prävalenz und Bedeutung natürlich vorkommender Precore-, Basal Core Promotor- und preS-Mutationen in einer großen europäischen Studienkohorte bei chronisch mit dem Hepatitis B Virus infizierten Patienten (2015) (0)
Immunological scars after cure of hepatitis C virus infection: Long-HepC? (2023) (0)
Treating hepatitis D with bulevirtide - Real-world experience from 114 patients. (2023) (0)
Distinct profiles and kinetics of soluble inflammatory markers in patients with acute and chronic HCV-infections and SARS-CoV-2-infections: Implications for the long-term consequences of viral infections? (2023) (0)
Novel combined approaches to hepatitis C therapies (2003) (0)
A multicenter randomized-controlled trial of nucleos(t)ide analogue cessation in HBeAg-negative chronic hepatitis B. (2023) (0)
Targeting epigenetic imprints to modulate HBV-specific T cell responses (2023) (0)
Single cell analysis of HCV and heterologous virus-specific CD8+T cell responses in patients with chronic hepatitis C before and after HCV elimination (2023) (0)
The role of CXCR6+γδ T cells in chronic hepatitis B virus (HBV) infection (2023) (0)
Intra-host diversity of hepatitis E virus polymerase during sofosbuvir treatment (2023) (0)
[Step-by-step toward the perfect hepatitis C treatment for all genotypes]. (2015) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Markus Cornberg?

Markus Cornberg is affiliated with the following schools:

Hannover Medical School
University of Massachusetts Medical School

Markus Cornberg's Academic­Influence.com Rankings

Why Is Markus Cornberg Influential?

Markus Cornberg's Published Works

Published Works

What Schools Are Affiliated With Markus Cornberg?

Markus Cornberg's AcademicInfluence.com Rankings